Rhodionin and rhodionin can inhibit cytochrome P450 2D6 non-competitively with high specificity which could have implications for interactions with co-administered drugs; they can significantly suppress the elevation of the postprandial blood triglyceride level, suggests that they may be to the treatment of lifestyle-related diseases such as hyperlipidemia and exogeneous obesity and to health foods. Rhodionin has antioxidant activity, it exhibits potent 1,1-diphenyl-2-picryl-hydrazyl (DPPH) free radical scavenging activities, with IC50 values of 19.49 ± 0.21 uM.